Project Grant HT94252510699

This federal Project Grant award, issued by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate the molecular mechanisms underlying the adeno-to-squamous transition in non-small cell lung cancer treatment. The $703,410 award, with a project period from January 16, 2025 to December 31, 2029, aims to identify vulnerabilities in the chromatin regulators driving this adaptive...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to develop an innovative approach to treat lung cancer, the leading cause of cancer deaths in the U.S. The $635,248 award to Trustees of Boston University aims to create a self-amplifying ribonucleic acid (SARNA) technology encoding a bispecific T cell engager (BiTE) antibody. The key products and services include: Designing modified SARNA constructs encoding BiTE antibodies and...

This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $127,629 to Harvard T.H. Chan School of Public Health to conduct research on the role of human leukocyte antigen (HLA) variations in immune response and the efficacy of immune checkpoint inhibitor (ICI) monotherapy for non-small cell lung cancer (NSCLC). The key objectives are to: 1) identify the mechanisms linking germline and somatic HLA variations, somatic mutations,...

This $641,336 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University aims to advance immunotherapy for non-small cell lung cancer (NSCLC). The project will investigate how disrupting the GARP-TGFbeta axis in the tumor microenvironment using the anti-GARP antibody PIIO-1 can enhance CD8+ T cell function and overcome resistance to immune checkpoint blockade therapy in NSCLC patients. Key objectives include defining how GARP...

This $216,460 federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at Case Western Reserve University to define the features of the neoantigen-specific T cell response against the common EGFR L858R mutation in lung cancer. The objective is to understand how the L858R mutation generates an immunogenic neoantigen that can provoke T cell-mediated anti-tumor immunity. Key activities include: Fully characterizing the...

The National Cancer Institute (NCI) awarded a 3-year, $183,398 Project Grant to The Ohio State University under the Cancer Research Manpower (CFDA 93.398) program. The goal of the project is to elucidate the mechanisms by which tumor hypoxia (low oxygen) contributes to immune privilege and treatment resistance in non-small cell lung cancer (NSCLC) tumors. The researchers will investigate the use of mitochondrial inhibitors, such as papaverine (PPV) and SMV-32, to reoxygenate the NSCLC tumor...

The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded a $540,288 Project Grant to the University of Florida to research the role of bacterial-derived small molecules in improving the efficacy of immunotherapy for non-small cell lung cancer (NSCLC). The project aims to characterize a bacterial metabolite called BAC429, which has been shown to augment the anti-tumor effects of anti-PD-1 immunotherapy in preclinical models. The research will...

This $730,400 Project Grant award under the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the metabolic control of malignant cell states in lung adenocarcinoma (LUAD). The overarching goal is to determine how specific configurations of the tricarboxylic acid (TCA) cycle, a central metabolic pathway, contribute to the emergence and maintenance of LUAD cell states that...

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...

The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...